ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR 3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03053050
Recruitment Status : Active, not recruiting
First Posted : February 14, 2017
Last Update Posted : May 14, 2018
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.

Condition or disease Intervention/treatment Phase
Nonalcoholic Steatohepatitis Drug: SEL Drug: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 808 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
Actual Study Start Date : February 13, 2017
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : February 2023


Arm Intervention/treatment
Experimental: SEL 6 mg
SEL 6 mg plus placebo for up to 240 weeks
Drug: SEL
Tablets administered orally once daily
Other Names:
  • selonsertib
  • GS-4997

Drug: Placebo
Tablets administered orally once daily

Experimental: SEL 18 mg
SEL 18 mg plus placebo for up to 240 weeks
Drug: SEL
Tablets administered orally once daily
Other Names:
  • selonsertib
  • GS-4997

Drug: Placebo
Tablets administered orally once daily

Placebo Comparator: Placebo
Placebo for up to 240 weeks
Drug: Placebo
Tablets administered orally once daily




Primary Outcome Measures :
  1. Proportion of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis According to the NASH Clinical Research Network (CRN) Classification Without Worsening of NASH [ Time Frame: Week 48 ]
  2. Event-Free Survival (EFS) at Week 240 as Assessed by Time to the First Clinical Event [ Time Frame: Week 240 ]

Secondary Outcome Measures :
  1. Proportion of Participants Who have Progression to Cirrhosis by Week 48 [ Time Frame: Week 48 ]
  2. Proportion of Participants Who have a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 240 [ Time Frame: Week 240 ]
  3. Proportion of Participants Who Have a ≥ 1-Stage Improvement in Fibrosis at Week 48 [ Time Frame: Week 48 ]
  4. Proportion of Participants Who Have a ≥ 1-Stage Improvement in Fibrosis at Week 240 [ Time Frame: Week 240 ]
  5. Proportion of Participants Who Have NASH Resolution Without Worsening of Fibrosis at Week 48 [ Time Frame: Week 48 ]
  6. Proportion of Participants Who Have NASH Resolution Without Worsening of Fibrosis at Week 240 [ Time Frame: Week 240 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Liver biopsy consistent with NASH and bridging (F3 fibrosis) according to the NASH CRN classification in the opinion of the central reader
  • Has the following laboratory parameters at the screening visit:

    • Alanine aminotransferase (ALT) ≤ 8 x upper limit of normal (ULN)
    • Creatinine Clearance (CLcr) ≥ 30 milliliter/minute (mL/min), as calculated by the Cockcroft-Gault equation
    • Hemoglobin A1c (HbA1c) ≤ 9.5% (or serum fructosamine ≤ 381 μmol if HbA1c is unable to be resulted)
    • Total bilirubin ≤ 1.3 x ULN (unless an alternate etiology such as Gilbert's syndrome or hemolytic anemia is present)

Key Exclusion Criteria:

  • Prior history of decompensated liver disease including clinical ascites, hepatic encephalopathy (HE), or variceal bleeding
  • Child-Pugh (CP) score > 6, as determined at screening, unless due to therapeutic anti-coagulation
  • Model for End-stage Liver Disease (MELD) score > 12, as determined at screening, unless due to therapeutic anti-coagulation
  • Other causes of liver disease including, but not limited to, alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders, drug-induced hepatotoxicity, Wilson disease, iron overload, and alpha-1-antitryspin deficiency, based on medical history and/ or centralized review of liver histology.
  • History of liver transplantation
  • Current or history of hepatocellular carcinoma (HCC)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03053050


  Show 295 Study Locations
Sponsors and Collaborators
Gilead Sciences
Investigators
Study Director: Gilead Study Director Gilead Sciences

Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT03053050     History of Changes
Other Study ID Numbers: GS-US-384-1943
2016-004374-18 ( EudraCT Number )
First Posted: February 14, 2017    Key Record Dates
Last Update Posted: May 14, 2018
Last Verified: May 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases